Cationic and silicon substituents are introduced into polysaccharides thereby producing modified polysaccharides cationically substituted by quaternary ammonium groups and having a charge density of about 0.1 to about 2.5 meq/g, and further substituted by siliconate groups such that the modified polysaccharide has a silicon content of about 300 to about 5000 ppm. The modified polysaccharides have application in industrial, home care and personal care surface modifying formulations.

The present invention provides a novel drug delivery conjugated moiety for oral administration of a drug that is not suitable for oral administration or a pharmaceutically acceptable salt thereof. When the drug delivery conjugated moiety of the present invention or a pharmaceutically acceptable salt thereof is combined with a drug, which is not suitable for oral administration, and is administered orally, it exhibits an excellent absorption rate without decreasing the biological activities of the drug. Moreover, the drug delivery conjugated moiety of the present invention or a pharmaceutically acceptable salt thereof can be easily prepared in a few steps, which is very advantageous in terms of mass production.

Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R.sup.1 (Ib) wherein X is C(O), S(O) or SO.sub.2; Y is NR.sup.1R.sup.2 or R.sup.3; R.sup.1 is C.sub.1-6 alkyl substituted with 1, 2 or 3 groups independently selected from hydroxyl, sulphydryl and amine; R.sup.2 is H or C.sub.1-6 alkyl; and R.sup.3 is C.sub.1-6 alkyl; processes for modifying a capsular saccharide with the blocking groups; saccharide-protein conjugates comprising the modified capsular saccharide; processes for making the saccharide-protein conjugates, pharmaceutical compositions comprising the modified capsular saccharides and/or saccharide-protein conjugates; and methods and uses of the same.

Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R.sup.1 (Ib) wherein X is C(O), S(O) or SO.sub.2; Y is NR.sup.1R.sup.2 or R.sup.3; R.sup.1 is C.sub.1-6 alkyl substituted with 1, 2 or 3 groups independently selected from hydroxyl, sulphydryl and amine; R.sup.2 is H or C.sub.1-6 alkyl; and R.sup.3 is C.sub.1-6 alkyl; processes for modifying a capsular saccharide with the blocking groups; saccharide-protein conjugates comprising the modified capsular saccharide; processes for making the saccharide-protein conjugates, pharmaceutical compositions comprising the modified capsular saccharides and/or saccharide-protein conjugates; and methods and uses of the same.

An aqueous dispersion of fructan-containing particles, wherein the D.sub.50 of the fructan-containing particles lies between 2 μm and 50 μm and the solids content of the aqueous dispersion lies between 61 wt. % and 80 wt. %. Also described is a process for the preparation of an aqueous dispersion of fructan-containing particles comprising: bringing fructan and water together to form a mixture; optionally hydrolyzing a portion of the fructans in the mixture, such that at the end of this step between 5 wt. % and 25 wt. % of all fructans in the mixture are essentially non-soluble at room temperature; optionally bring the mixture into contact with a purification agent, followed by removal of the purification agent from the mixture; and concentrating the mixture such that the solids content lies between 61 and 80%.

The present invention relates to the synthesis of GPI-related surface antigens of the parasite Toxoplasma gondii (T. gondii) and the resulting products obtained. These synthetic compounds are suitable for diagnosis of toxoplasmosis, as well as vaccine against toxoplasmosis, a diseases caused by infection with T. gondii.

The present disclosure discloses an ultrasonic-assisted method of extracting a pectin rich in RG-I. The method includes: (1) dispersing citrus peel powders in an alkaline solution containing sodium borohydride; (2) placing a solution obtained in step (1) in a water bath of 25 to 40° C., and performing an ultrasonic treatment on the solution obtained in step (1); (3) centrifuging the solution subjected to step (2) at a speed of 6000-8000 rpm to remove residues, retaining a supernatant, and precipitating a pectic polysaccharide with absolute ethanol; and (4) adding water to the pectic polysaccharide precipitant subjected to step (3) to obtain a redissolved solution, transferring the solution to a dialysis bag with a molecular weight cut-off of 3000 to 3500 Da, dialyzing for 48 hours, and freeze-drying in a vacuum freezer to obtain the pectin rich in RG-I.

Disclosed is a method for joint recovery of pectin from citrus peels and alkaline/acidic processing water from citrus canning, including the following steps: adding fresh citrus fruit peels to alkali/acid processing water from citrus fruit canning for extracting; filtering the resulting mixture, adding to the resulting filtrate 95% ethanol 1 to 3 times the volume of the filtrate, and then adjusting the pH to a range of 3.5 to 7, followed by standing for 10 minutes to 4 hours; filtering the product after standing, washing the resulting precipitate with 50% to 70% ethanol, and drying and crushing, thereby obtaining pectin. The method makes full use of waste resources from citrus fruit canning, solves the problem of pollution by processing discharge water, and has the advantages of saving the preparation cost of pectin from citrus peels, and improving the solubility of recovered pectin.

The present invention generally relates to the field of detecting and preventing infectious diseases caused by Enterococcus faecalis and/or Enterococcus faecium. More specifically, the invention relates to an Enterococcus faecalis and/or Enterococcus faecium antigen which comprises at least one unit having the following general formula: ##STR00001##

Compositions comprising metal ions or clusters such as ferrous and/or ferric iron compounds or magnesium, zinc, lanthanum and other metal ion compounds and fiber components such as gum Arabic in a complex, methods for preparing such compositions of matter, and the use thereof for treatment of adsorbing certain accessible targets in the gastrointestinal tract and in an extracorporeal system, are provided herein.